人工智能利用单导联心电图预测心力衰竭风险
该回顾性队列研究在耶鲁纽黑文健康系统及英国生物银行、ELSA-Brasil队列中,用噪声适应AI-ECG模型从I导联心电图预测左室收缩功能障碍相关心衰风险;阳性筛查结果与心衰风险升高3至7倍相关,模型判别力0.723至0.828,优于PCP-HF与PREVENT方程。
要点
- AI-ECG从I导联心电图预测新发心衰,判别力0.723至0.828。
- 阳性筛查与心衰风险升高3至7倍相关,独立于年龄、性别、合并症与死亡竞争风险。
- 在PCP-HF和PREVENT方程基础上加入AI-ECG可提高判别与重分类。
核心结论
- 噪声适应AI-ECG模型利用I导联心电图估计心衰风险,在多国队列中提示其可作为心衰风险分层策略,但需前瞻性研究验证。
研究设计与样本
- 数据分析时间为2023年9月至2025年2月。
主要发现
- YNHHS中位随访4.6年3697例(1.9%)发生心衰,UKB中位3.1年46例(0.1%),ELSA-Brasil中位4.2年31例(0.2%)。
- AI-ECG阳性筛查与心衰风险升高3至7倍相关,模型概率每增加0.1风险比升高27%至65%。
- 新发心衰判别力:YNHHS 0.723(95%CI 0.694-0.752),UKB 0.736(95%CI 0.606-0.867),ELSA-Brasil 0.828(95%CI 0.692-0.964)。
关键数值与推荐
- 加入PCP-HF后Harrel C统计量差值0.080至0.107,加入PREVENT后差值0.069至0.094。
- 对照PCP-HF的IDI为0.091至0.205,对照PREVENT的IDI为0.068至0.192。
- 对照PCP-HF的NRI为18.2%至47.2%,对照PREVENT的NRI为11.8%至47.5%。
临床怎么用
- 可考虑用可穿戴或便携设备采集的I导联心电图进行社区大规模心衰风险初筛。
- AI-ECG预测可叠加在PCP-HF或PREVENT方程之上改善风险分层。
局限性
- 研究为回顾性设计,UKB与ELSA-Brasil心衰事件数较少,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite the availability of disease-modifying therapies, scalable strategies for heart failure (HF) risk stratification remain elusive. Portable devices capable of recording single-lead electrocardiograms (ECGs) may enable large-scale community-based risk assessment. OBJECTIVE: To evaluate whether an artificial intelligence (AI) algorithm can predict HF risk from noisy single-lead ECGs. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of individuals without HF at baseline was conducted among individuals with conventionally obtained outpatient ECGs in the integrated Yale New Haven Health System (YNHHS) and prospective population-based cohorts of the UK Biobank (UKB) and the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Data analysis was performed from September 2023 to February 2025. EXPOSURE: AI-ECG-defined risk of left ventricular systolic dysfunction (LVSD). MAIN OUTCOMES AND MEASURES: Among individuals with ECGs, lead I ECGs were isolated and a noise-adapted AI-ECG model (to simulate ECG signals from wearable devices) trained to identify LVSD was deployed. The association of the model probability with new-onset HF, defined as the first HF hospitalization, was evaluated. The discrimination of AI-ECG was compared against 2 risk scores for new-onset HF (Pooled Cohort Equations to Prevent Heart Failure [PCP-HF] and Predicting Risk of Cardiovascular Disease Events [PREVENT] equations) using the Harrel C statistic, integrated discrimination improvement, and net reclassification improvement. RESULTS: There were 192 667 YNHHS patients (median [IQR] age, 56 [41-69] years; 111 181 women [57.7%]), 42 141 UKB participants (median [IQR] age, 65 [59-71] years; 21 795 women [51.7%]), and 13 454 ELSA-Brasil participants (median [IQR] age, 51 [45-58] years; 7348 women [54.6%]) with baseline ECGs. A total of 3697 (1.9%) developed HF in YNHHS over a median (IQR) of 4.6 (2.8-6.6) years, 46 (0.1%) in UKB over a median (IQR) of 3.1 (2.1-4.5) years, and 31 (0.2%) in ELSA-Brasil over a median (IQR) of 4.2 (3.7-4.5) years. A positive AI-ECG screening result for LVSD was associated with a 3- to 7-fold higher risk for HF, and each 0.1 increment in the model probability was associated with a 27% to 65% higher hazard across cohorts, independent of age, sex, comorbidities, and competing risk of death. AI-ECG's discrimination for new-onset HF was 0.723 (95% CI, 0.694-0.752) in YNHHS, 0.736 (95% CI, 0.606-0.867) in UKB, and 0.828 (95% CI, 0.692-0.964) in ELSA-Brasil. Across cohorts, incorporating AI-ECG predictions alongside PCP-HF and PREVENT equations was associated with a higher Harrel C statistic (difference in addition to PCP-HF, 0.080-0.107; difference in addition to PREVENT, 0.069-0.094). AI-ECG had an integrated discrimination improvement of 0.091 to 0.205 vs PCP-HF and 0.068 to 0.192 vs PREVENT; it had a net reclassification improvement of 18.2% to 47.2% vs PCP-HF and 11.8% to 47.5% vs PREVENT. CONCLUSIONS AND RELEVANCE: Across multinational cohorts, a noise-adapted AI-ECG model estimated HF risk using lead I ECGs, suggesting a potential HF risk-stratification strategy requiring prospective study using wearable and portable ECG devices.
引用
- Dhingra, Aminorroaya, Pedroso, et al. Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms. JAMA Cardiol. 2025. PMID: 40238120. doi:10.1001/jamacardio.2025.0492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。